BGPartner advises Araris Biotech in a CHF 24m financing round

BGPartner has advised Araris Biotech in a CHF 24 million financing round, involving the two co-lead investors 4BIO Capital and Pureos Bioventures.

Araris Biotech, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the proceeds to support advancement of lead ADCs in preclinical and into clinical development.

The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille and the Institute for Follicular Lymphoma Innovation. The round also included participation from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine.

BGPartner has assisted Araris Biotech in the negotiations and advised on all Swiss legal matters regarding this financing round. The team was led by partner Oliver Gnehm (pictured left) and further consisted of senior associate Thomas Gysin (pictured right).

BGPartner advises Araris Biotech in a CHF 24m financing round


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram